Humacyte (HUMA) Stock Price, News & Analysis

Company Overview

Humacyte, Inc. is a biotechnology company developing and commercializing off-the-shelf, bioengineered human tissues for use in vascular repair and regenerative medicine. Its technology is based on human acellular tissue-engineered vessels, which are designed to provide durable vascular conduits without requiring a patient-specific donor vessel.

The company’s lead product, Symvess, is an acellular tissue-engineered vessel approved by the U.S. Food and Drug Administration for the treatment of extremity arterial injuries in adults when emergency vascular repair is needed and a suitable vein is unavailable or inappropriate. Humacyte is also advancing its vascular products for potential use in other areas, including vascular trauma, arteriovenous access for hemodialysis, and selected cardiovascular and pediatric applications.

Founded in 2004 and headquartered in Durham, North Carolina, Humacyte was co-founded by Dr. Laura Niklason, who serves as chief executive officer. The company’s development and commercial activities are primarily focused on the United States, with its technology intended for use by hospitals and medical professionals in vascular and surgical care.

Key Stats

• Today's Range: $0.55 to $0.57
• 50-Day Range: $0.55 to $0.74
• 52-Week Range: $0.53 to $2.55
• Volume: 2.62 million shs
• Average Volume: 4.54 million shs
• Market Capitalization: $154.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.54
• Consensus Rating: Moderate Buy

Humacyte Stock Analysis - MarketRank™

Humacyte scored higher than 41% of companies evaluated by MarketBeat, and ranked 668th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Humacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Humacyte has a consensus price target of $6.54, representing about 1,073.8% upside from its current price of $0.56.

Amount of Analyst Coverage

Humacyte has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Humacyte are expected to grow in the coming year, from ($0.40) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Humacyte is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Humacyte is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Humacyte has a P/B Ratio of 27.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.82% of the float of Humacyte has been sold short.

Short Interest Ratio / Days to Cover

Humacyte has a short interest ratio ("days to cover") of 7.25.

Change versus previous month

Short interest in Humacyte has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Humacyte does not currently pay a dividend.

Dividend Growth

Humacyte does not have a long track record of dividend growth.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.27

News Sentiment

Humacyte has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Humacyte this week, compared to 4 articles on an average week.

Search Interest

Only 9 people have searched for HUMA on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Humacyte insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.10% of the stock of Humacyte is held by insiders.

Percentage Held by Institutions

44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HUMA
• CIK: 1818382
• Web: www.humacyte.com
• Phone: 919-313-9633
• Fax: N/A
• Employees: 184
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Humacyte: $6.54
• High Price Target: $25.00
• Low Price Target: $1.00
• Potential Upside/Downside: +1,073.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.83 million
• Net Margins: -4,556.29%
• Pretax Margin: -4,560.82%
• Return on Equity: -983.32%
• Return on Assets: -88.84%

Debt

• Debt-to-Equity Ratio: 2.07
• Current Ratio: 6.21
• Quick Ratio: 5.74

Sales & Book Value

• Annual Sales: $2.04 million
• Price / Sales: 75.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 27.87

Miscellaneous

• Outstanding Shares: 277,800,000
• Free Float: 269,186,000
• Market Cap: $154.82 million
• Optionable: Optionable
• Beta: 2.45